Stage 1 enters agreement with Leinco Technologies

August 11, 2017

Novel Tests for early cancer detection become reality

Little Rock, AR, August 10, 2017–  Stage I Diagnostics (Little Rock, AR) has officially entered into an agreement with Leinco Technologies (St. Louis, MO) to expand the availability  of Stage I’s blood tests for ovarian and prostate cancer.  These tests quantitatively measure the levels/expression of certain aggressive cancer causing proteins in the blood with a simple blood test. Stage I was incubated at UAMS and Arkansas Bio-Ventures while researching and identifying novel genes that are involved in the actual tumor growth and spread.  The company was founded by Dr. Timothy O’Brien in 2005.

“This relationship gives Stage I Diagnostics an incredible opportunity to offer early cancer diagnostics worldwide.  We know that Leinco Technologies is a leader in antibody development and distribution and we feel fortunate to partner with them.”-Don E. Fowler, President/CEO Stage I Diagnostics

Leinco Technologies, Inc. is a US biotechnology company founded in 1992 as a specialty manufacturer and distributor of early discovery research products including antibodies, recombinant proteins, ELISA kits, and other life sciences solutions. Leinco Technologies has distribution and sales channels in the life science research, drug discovery and clinical diagnostics markets.

“We look forward to representing Stage I Diagnostics for commercialization of their novel oncology protein biomarker assays and helping them further develop these assays for use on the Luminex multiplexing panel.”-Pat Leinert, Founder and CEO Leinco Technologies

Stage I’s mission is “early detection of aggressive cancers in order to give patients better outcomes.”

# # #

If you would like more information about this topic, please contact Don E. Fowler at 501-353-0014 or email at



Contact:  Don E. Fowler
Telephone:  501-353-0014


Stage I Leinco Press Rel FINAL.docx